Hepcidin in iron overload disorders

被引:342
作者
Papanikolaou, G
Tzilianos, M
Christakis, JI
Bogdanos, D
Tsimirika, K
MacFarlane, J
Goldberg, YP
Sakellaropoulos, N
Ganz, T
Nemeth, E
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA
[2] Univ Athens, Dept Med 1, Thessaloniki, Greece
[3] Corfu Gen Hosp, Blood Bank Unit, Thessaloniki, Greece
[4] Theagen Canc Ctr, Dept Hematol, Thessaloniki, Greece
[5] Xenon Pharmaceut, Burnaby, BC, Canada
关键词
D O I
10.1182/blood-2004-12-4844
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hepcidin is the principal regulator of iron absorption in humans. The pepticle inhibits cellular iron efflux by binding to the iron export channel ferroportin and inducing its internalization and degradation. Either hepcidin deficiency or alterations in its target, ferroportin, would be expected to result in dysregulated iron absorption, tissue maldistribution of iron, and iron overload. Indeed, hepcidin deficiency has been reported in hereditary hemochromatosis and attributed to mutations in HFE, transferrin receptor 2, hemojuvelin, and the hepcidin gene itself. We measured urinary hepcidin in patients with other genetic causes of iron overload. Hepcidin was found to be suppressed in patients with thalassemia syndromes and congenital dyserythropoietic anemia type 1 and was undetectable in patients with juvenile hemochromatosis with HAMP mutations. Of interest, urine hepcidin levels were significantly elevated in 2 patients with hemochromatosis type 4. These findings extend the spectrum of iron disorders with hepcidin deficiency and underscore the critical importance of the hepcidin-ferroportin interaction in iron homeostasis. (c) 2005 by The American Society of Hematology.
引用
收藏
页码:4103 / 4105
页数:3
相关论文
共 21 条
  • [1] Decreased hepcidin mRNA expression in thalassemic mice
    Adamsky, K
    Weizer, O
    Amariglio, N
    Breda, L
    Harmelin, A
    Rivella, S
    Rachmilewitz, E
    Rechavi, G
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (01) : 123 - 124
  • [2] Medical progress: Disorders of iron metabolism
    Andrews, NC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (26) : 1986 - 1995
  • [3] Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis
    Bridle, KR
    Frazer, DM
    Wilkins, SJ
    Dixon, JL
    Purdie, DM
    Crawford, DHG
    Subramaniam, VN
    Powell, LW
    Anderson, GJ
    Ramm, GA
    [J]. LANCET, 2003, 361 (9358) : 669 - 673
  • [4] Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3)
    Cazzola, M
    Cremonesi, L
    Papaioannou, M
    Soriani, N
    Kioumi, A
    Charalambidou, A
    Paroni, R
    Romtsou, K
    Levi, S
    Ferrari, M
    Arosio, P
    Christakis, J
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (02) : 539 - 546
  • [5] Complications of β-thalassemia major in north America
    Cunningham, MJ
    Macklin, EA
    Neufeld, EJ
    Cohen, AR
    [J]. BLOOD, 2004, 104 (01) : 34 - 39
  • [6] FINCH C, 1994, BLOOD, V84, P1697
  • [7] Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding
    Fleming, RE
    Sly, WS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (04) : 521 - 522
  • [8] Hepcidin in iron metabolism
    Ganz, T
    [J]. CURRENT OPINION IN HEMATOLOGY, 2004, 11 (04) : 251 - 254
  • [9] Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
    Nemeth, E
    Valore, EV
    Territo, M
    Schiller, G
    Lichtenstein, A
    Ganz, T
    [J]. BLOOD, 2003, 101 (07) : 2461 - 2463
  • [10] Hepcidin is decreased in TFR2 hemochromatosis
    Nemeth, E
    Roetto, A
    Garozzo, G
    Ganz, T
    Camaschella, C
    [J]. BLOOD, 2005, 105 (04) : 1803 - 1806